Bruce Kirenga J
ID: UNCST-2019-R001460
|
Characteristics of persons screened, tested and diagnosed with corona virus disease-19 at health facilities in Uganda
REFNo: HS657ES
Main objective:
To estimate the cumulative incidence of a composite treatment outcome of admission to intensive care unit, mechanical ventilation or death among COVID-19 confirmed patients attending health facilities in Uganda for COVID-19 care.
Secondary objectives:
1. To describe the socio-demographic, behavioral and clinical characteristics of patients screened for and or receiving COVID-19 care at health facilities in Uganda
2. To determine the screening and testing outcomes of COVID-19 infections among patients at health facilities in Uganda
|
Uganda |
2020-11-25 |
2023-11-25 |
Medical and Health Sciences |
|
Non-degree Award |
.jpg)
|
Bruce Kirenga J
ID: UNCST-2019-R001460
|
Assessment of the feasibility of collection of COVID 19 Immune/convalescent Plasma in Uganda
REFNo: HS684ES
General objective
The overall objective of this project is to assess the feasibility collecting and storing of COVID-19 convalescent plasma (CCP) in Uganda.
Specific objectives
1. To determine the proportion of Ugandan COVID-19 survivors who consent for CP donation
2. To determine the levels of SARS-CoV-2 virus antibodies among Ugandan COVID 19 recoveries
3. To establish a biobank of well annotated and well characterized plasma aliquots from COVID 19 recovered patients for future biomedical studies
|
Uganda |
2020-06-11 |
2023-06-11 |
Medical and Health Sciences |
|
Non-degree Award |
|
Bruce Kirenga J
ID: UNCST-2019-R001460
|
Assessment of safety and efficacy of COVID-19 Convalescent Plasma for treatment of COVID-19 in adults in Uganda; A randomized controlled trial
(CCP TRIAL)
REFNo: HS816ES
General objective
The overall objective of this project is to assess the safety and efficacy of COVID-19 convalescent plasma in the treatment of COVID-19 in Uganda.
Primary objective
1. To determine the efficacy of COVID-19 Convalescent Plasma, as measured by time to RT-PCR negativity of COVID-19 patients treated with COVID-19 Convalescent Plasma.
Secondary objectives
1. To assess the safety of COVID-19 Convalescent Plasma in the treatment of COVID-19 patients in Uganda
2. To document the time to symptom decrease of patients with positive SARS-CoV-2 RT PCR treated with CCP compared to those on standard of care
3. To assess the ability of CCP therapy to stop progression to severe/critical forms of disease
|
Uganda |
2020-08-05 |
2023-08-05 |
Medical and Health Sciences |
|
Non-degree Award |
|
Bruce Kirenga J
ID: UNCST-2019-R001460
|
Strategies for resolving the gap in Adolescent TB care in Uganda: A pilot cluster randomized-controlled trial
REFNo: HS1042ES
1.To develop an adolescent friendly TB screening package in Ugandan health facilities.
2.To evaluate the effectiveness of an adolescent friendly screening package for TB in Ugandan health facilities
3.To ascertain the cost effectiveness of rolling out an adolescent friendly TB screening intervention in Ugandan health facilities
|
Uganda |
2021-03-15 |
2024-03-15 |
Medical and Health Sciences |
|
Non-degree Award |
|
Bruce Kirenga J
ID: UNCST-2019-R001460
|
SITUATIONAL ANALYSIS OF EXISTING CAPACITY AND RESOURCES AT MEAKERERE UNIVERSITY TO SUPPORT A RESEARCH TRAINING PROGRAM FOCUSING ON NON-COMMUNICABLE DIEASES AND AGEING AMONG PEOPLE LIVING WITH HIV/AIDS
REFNo: HS1252ES
General Objective
To describe existing research capacity, training and resources within the MakCHS that can be leveraged to design a successful NCD-HIV-Ageing training program at MakCHS
Specific Objectives
To describe existing NCD, HIV and ageing research at Makerere University and collaborating institutions within MakCHS and Mulago Hospital complex.
To define the existing NCD, HIV and ageing training activities at Makerere University and collaborating institutions within MakCHS and Mulago Hospital complex.
To outline the existing resources to support research and training on NCDs, HIV and ageing at Makerere University and other collaborating institutions within MakCHS and Mulago Hospital complex.
To define a pool of potential trainees that could be recruited for research training on NCDs, HIV and ageing at Makerere University and collaborating institutions within MakCHS and Mulago Hospital complex
|
Uganda |
2021-04-13 |
2024-04-13 |
Medical and Health Sciences |
|
Non-degree Award |
|
Bruce Kirenga J
ID: UNCST-2019-R001460
|
MID-TERM PROJECT EVALUATION: CAPACITY BUILDING OF NATIONAL TUBERCULOSIS CONTROL
REFNo: HS1253ES
Primary objectives
1. To analyze the matching rate of M-KIT testing results between NTRL and Kumoh National Institute of Technology (KIT).
2. To analyze the change in TB case detection rate in Bukomansimbi from 2017 to 2020
Secondary objectives
1. To analyze the change in TB treatment success rate in Bukomansimbi from 2017 to 2020
2. To analyze the change in TB case notification rate in Bukomansimbi from 2017 to 2020
3. To analyze the change in DOT coverage in Bukomansimbi from 2017 to 2020
4. To analyze the trend of the number of DST performed in NTRL from 2017 to 2020
5. To review the satisfaction of NTRL training program
6. To identify potential activities to incorporate into the ongoing project
|
Uganda |
2021-07-01 |
2024-07-01 |
Medical and Health Sciences |
|
Non-degree Award |
|
Bruce Kirenga J
ID: UNCST-2019-R001460
|
Uganda Gender and Tuberculosis Key Populations Assessment
REFNo: HS1864ES
1. To establish the gender differences evident in TB care cascade (diagnosis through treatment) records in Uganda.
2. To determine the gender barriers and facilitators to TB prevention, diagnosis, treatment and treatment completion in Uganda.
3. To generate information to guide the listing of TB KVPs relevant to Uganda context, and for designing interventions for addressing the gaps among prioritized KVPs.
4. To determine to what extent the National TB response (NSP and policies/guidelines) addresses gender and KVP issues in Uganda.
|
Uganda |
2022-03-14 |
2025-03-14 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Bruce Kirenga J
ID: UNCST-2019-R001460
|
Lung Cancer in East Africa in Relation to HIV-1 Infection: Epidemiological, Molecular Characterization and Imaging (LCH Study)
REFNo: HS1922ES
1. To determine the clinical epidemiology of lung cancer and its relationship to HIV-1 infection in Uganda and Tanzania.
2. To determine the molecular determinants of lung cancer in HIV infected and uninfected individuals in Uganda and Tanzania
3. To Characterize Lung Cancer in HIV infected and uninfected populations in Uganda and Tanzania using Artificial Intelligence.
|
Uganda |
2022-02-28 |
2025-02-28 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Bruce Kirenga J
ID: UNCST-2019-R001460
|
Estimating the real-world effectiveness and determinants of effectiveness China Manufactured and other COVID-19 vaccines in Uganda
REFNo: HS2422ES
To determine the overall and product-specific rate of breakthrough infections (laboratory-confirmed SARS-CoV-2) among adult Ugandans vaccinated with China manufactured and other COVID-19 vaccines in Uganda,To estimate COVID-19 vaccine effectiveness (CVE) for more severe outcomes (e.g., ICU admission, or in-hospital mortality) and its determinants in among adults diagnosed with COVID-19 in Uganda,To determine the overall and product-specific effectiveness of China manufactured and other COVID 19 vaccines against symptomatic COVID-19 disease among adults diagnosed with COVID 19 in Uganda,
|
Uganda |
2022-09-06 14:21:36 |
2025-09-06 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Bruce Kirenga J
ID: UNCST-2019-R001460
|
SAFETY, PHARMACOKINETICS AND PRELIMINARY EFFICACY OF HERBAL PRODUCTS FOR THE TREATMENT OF ACUTE RESPIRATORY VIRAL INFECTIONS INCLUDING SARS-COV2 IN UGANDA; PHASE 2A OPEN LABEL CLINICAL TRIAL
REFNo: HS2548ES
The general objective is to assess the safety, pharmacokinetics and preliminary efficacy of TazCoV and Vidicine for the treatment of acute respiratory viral infections (SARS-CoV2, RSV and Influenza A/B) in Uganda.
Specific objectives
1. To determine the safety and pharmacokinetics of TAZCOV and Vidicine herbal products among adult patients with acute respiratory infections due to laboratory-confirmed SARS-CoV2, RSV and Influenza A/B
2. To determine the extent of SARS-CoV2, RSV and Influenza A/B viral clearance among adult patients with acute viral respiratory infection treated using TAZCOV and Vidicine
3. To establish time-to-remission of symptoms among patients with acute respiratory infections due to laboratory-confirmed SARS-CoV2, RSV and Influenza treated with TAZCOV or Vidicine
4. To evaluate disease progression among patients with acute respiratory infections due to laboratory-confirmed SARS-CoV2, RSV and Influenza treated with TAZCOV or Vidicine
|
Uganda |
2022-11-29 12:38:24 |
2025-11-29 |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Bruce Kirenga J
ID: UNCST-2019-R001460
|
Ring vaccination trial to evaluate the efficacy and safety of Sudan ebolavirus vaccines in Uganda
REFNo: HS2574ES
Probable SUVD and death from confirmed SUVD ,main secondary objective is to assess the safety of the vaccine by monitoring weekly for 21 days any adverse reactions to vaccination and any other serious adverse events,The primary analysis will be of laboratory-confirmed SUVD (from samples taken either while living, or within 48 hours of death),
|
Uganda |
2022-11-23 15:04:05 |
2025-11-23 |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Bruce Kirenga J
ID: UNCST-2019-R001460
|
THE SECOND UGANDA NATIONAL ANTI-TUBERCULOSIS DRUGS RESISTANCE SURVEY(DRS2)
REFNo: HS2652ES
To identify the demographic and clinical factors associated with drug resistance in Uganda including HIV, tobacco smoking, diabetes and alcoholism.,To determine circulating strains of MTB in the general population among PBCs in Uganda.,To determine the prevalence of resistance mutations to all first- and second-line drugs in use in Uganda.,To determine the prevalence and patterns of drug resistance to fluoroquinolones, Bedaquiline, Delamanid, clofazimine, amikacin, and Linezolid among patients with confirmed RR-TB in Uganda.,To determine the prevalence of resistance to HRZE among new and previously treated PBC patients in Uganda.,To measure the prevalence of RR-TB among bacteriologically confirmed pulmonary TB (PBC) patients in Uganda. ,
|
Uganda |
2023-02-20 13:22:01 |
2026-02-20 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Bruce Kirenga J
ID: UNCST-2019-R001460
|
A multiple arm, multiple stage (MAMS), phase 2B/C, open label, randomized, controlled platform trial to evaluate experimental arms including an increased dose of rifampicin, an optimized dose of pyrazinamide, moxifloxacin and sutezolid, in adult subjects with newly diagnosed, smear-positive pulmonary tuberculosis
REFNo: HS2644ES
Primary Efficacy Objective:
Rifampicin- containing experimental arms (arms 1,2)
To evaluate whether one or more of two experimental regimens based on
optimized dose rifampicin, optimized dose of pyrazinamide, and moxifloxacin
given for 12, respectively 17 weeks, are superior to standard treatment given for
26 weeks, as assessed by time to sputum culture conversion to negative in liquid
media.
Sutezolid-containing experimental arm (arm 4)
To evaluate whether the efficacy of an experimental regimen composed of
sutezolid, delamanid, bedaquiline, and moxifloxacin given for 17 weeks is
superior to standard treatment given for 26 weeks, as assessed by time to
sputum culture conversion to negative in liquid media.
Secondary Objectives This study’s secondary objectives are:
Efficacy
To assess treatment efficacy based on proportion of patients with relapse
free outcome at 12 months after randomization.
To assess treatment efficacy based on the rate of decline of bacterial load
measured by the Molecular Bacterial Load Assay
To rank the relative efficacy of the experimental four-drug combinations
for the treatment of pulmonary tuberculosis within the first twelve weeks
of treatment, and select the most efficient experimental treatment
regimen or regimens for further development.
Safety and Tolerability
To assess the frequency, severity, and type of adverse events (AEs), and AErelated
treatment discontinuations.
Pharmacokinetics
To describe the pharmacokinetics of the drugs and doses used, and to assess
possible relationships between pharmacokinetic parameters of the various drugs and between pharmacokinetic parameters and participant characteristics.
Pharmacodynamics To describe relationships between pharmacokinetic parameters on the one hand and efficacy and safety endpoints on the other hand.
|
Uganda |
2023-04-11 15:27:11 |
2026-04-11 |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Bruce Kirenga J
ID: UNCST-2019-R001460
|
AIr Pollution Effects on Transmission of Mycobacterium tuberculosis in Urban Slum Communities in Uganda.
REFNo: HS3084ES
Overall, the purpose of the study is to ensure the development team have a deep understanding of the considerations surrounding use of a respiratory treatment device. This includes the most significant challenges and opportunities in use of a respiratory treatment device. As such, the present study will form the foundation of concept ideation for a respiratory treatment device. Specific study objectives include the following: (1) Capture potential end user needs in both urban and rural locations (2) Capturing participant’s COVID-19 pandemic experience (3) Gaining an understanding of the COVID-19 pandemic response, and (4) Gaining an understanding of the healthcare system in which a respiratory device may be distributed/prescribed/administered/used/disposed.,4.2.2 Specific objectives I. To enroll subjects with active pulmonary TB (index cases) and assess their source strength in an urban slum community in Uganda II. To enroll household contacts (HC) of index cases and measure Mtb transmission to Mtb-naïve (those with negative Mtb infection tests) household contacts (people living in the same home as the index case) in an urban slum community in Uganda III. To characterize exposures to air pollution in both TB index cases and their household contacts in an urban slum community in Uganda,Main Objective The overall purpose of this study is to determine the extent to which particulate matter (PM) air pollution exposure affects the source strength (quantity of Mtb (Mycobacterium tuberculosis) in respiratory aerosol) of persons with active tuberculosis (TB) and the susceptibility to infection with Mycobacterium tuberculosis in their contacts. Both source strength and susceptibility determine transmission of Mtb in the community,
|
Uganda |
2024-05-31 18:24:06 |
2027-05-31 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Bruce Kirenga J
ID: UNCST-2019-R001460
|
SOLIDARITY TRIAL-A phase I/II Randomized Placebo controlled trial to evaluate the Safety and Immunogenicity of Sudan Ebolavirus in Uganda
REFNo: HS3190ES
Phase I (rVSV-SUDV)
1. To determine the safety of rVSV-SUDV candidate SUDV vaccine among adult healthy volunteers in Uganda.
2. To determine the immunogenicity of rVSV-SUDV candidate SUDV vaccine.
Phase II (ChAdox1, CAd3 and rVSV-SUDV)
Primary objectives
1. To determine the safety of ChAdox1, CAd3 and rVSV-SUDV candidate SUDV vaccines among healthy volunteers and persons with stable comorbidities.
2. To determine the immunogenicity of ChAdox1, CAd3 and rVSV-SUDV candidate SUDV vaccines.
Secondary objectives
1. To determine the durability of SUDV-specific induced immune responses following vaccination.
2. To determine the factors associated with optimal vaccine-induced immune responses.
3. To determine the putative cross reactivity by the SUDV vaccine candidates against other ebolaviruses (e.g. Bundibugyo ebolavirus (BUDV) and EBOV).
Exploratory objectives
1. To determine the effect of SUDV vaccines on host gene expression.
2. To determine the T and B cell specific responses and immune profiling in response to vaccination.
3. To determine the effect of SUDV vaccines on the host metabolome.
4. To determine the effect of SUDV vaccines on host innate immune responses.
|
Uganda |
2024-02-26 13:31:25 |
2027-02-26 |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Bruce Kirenga J
ID: UNCST-2019-R001460
|
Assessment of Feasibility, Acceptability and Effectiveness of Training Village Health teams On Household Air Pollution Using Teach BOX
REFNo: HS3723ES
1. To assess the feasibility and acceptability of training Village Health Teams on Household Air Pollution using TeachBox in Jinja district Uganda.
2. To assess the effectiveness of training Village Health Teams on Household Air Pollution using TeachBox in Jinja district Uganda
|
Uganda |
2024-02-09 23:25:22 |
2027-02-09 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Bruce Kirenga J
ID: UNCST-2019-R001460
|
Household Energy Related Burns Study - Burden and Context Evaluation in Hospital Settings in Uganda (CLEAN-Air (Africa) HERBS)
REFNo: HS3614ES
1. To conduct a retrospective review of hospital records (up to 5 years) to determine the burden of household fuel-related burns and their short-term impacts on affected individuals in Uganda.
2. To conduct a survey to examine the occurrence , severity and determining the circumstances of hospital treated burns caused by household energy use in a study period of 24 months, using the WHO Burn Registry data collection form.
3. To conduct a qualitative study gaming health care workers on knowledge, attitudes and practices of burns care including data collection of burn-related cases
|
Uganda |
2024-01-24 22:50:16 |
2027-01-24 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Bruce Kirenga J
ID: UNCST-2019-R001460
|
Implementation research on the tailored, multidisciplinary Non-Communicable Disease prevention package targeting air pollution exposure in mid- to late adolescents in Uganda: FRESHAIR-4-LIFE
REFNo: SS2485ES
To address the burden of NCDs by gaining knowledge, resources and capacity to optimize the implementation of tailored preventive intervention packages, targeting adolescents’ exposure to risk factors like tobacco (use) and AP in disadvantaged populations worldwide. In Uganda, we will focus on air pollution.,
|
Uganda |
2024-08-06 17:44:22 |
2027-08-06 |
Social Science and Humanities |
Non-Clinical Trial |
Non-degree Award |
|
Bruce Kirenga J
ID: UNCST-2019-R001460
|
INVENTORY, EFFECTIVENESS, AND SAFETY OF NOTIFIED NATURAL MEDICINES FOR THE TREATMENT OF DIABETES IN UGANDA: A PROSPECTIVE OBSERVATIONAL STUDY. A CONAT PROGRAM
REFNo: HS4356ES
The general objective is to create an inventory of NDA-notified natural or herbal medicines commonly used in the management of diabetes in adult patients in Uganda, and evaluate their preliminary effectiveness and safety
Specific objectives are:
1. To establish the NDA-notified natural or herbal medicines commonly used in the management of DM among adults in Uganda
2. To determine the preliminary effectiveness of the NDA-notified natural or herbal medicines in lowering blood glucose levels when used in isolation or as complementary to conventional DM medicines
3. To assess the effect of the NDA-notified natural or herbal medicines on specific cardiometabolic characteristics of adult patients with DM in Uganda, when used in isolation or as complementary to conventional DM medicine
4. To determine the safety profile of the NDA-notified natural or herbal medicines when used in isolation or as complementary to conventional DM medicine in adult patients in Uganda
|
Uganda |
2024-07-02 12:54:13 |
2027-07-02 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Bruce Kirenga J
ID: UNCST-2019-R001460
|
Assessment of Longitudinal Lung Function and Sleep Disordered Breathing in COPD Patients in Uganda
REFNo: HS4817ES
1.Assess longitudinal lung function and respiratory symptoms among adults with COPD in Uganda.
2.Determine whether baseline radiographic imaging and inflammatory markers can predict exacerbations at one year among those with COPD.
3.Assess nocturnal sleep patterns and the association between sleep disordered breathing and quality of life.
|
Uganda |
2024-08-22 11:27:08 |
2027-08-22 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
| View |
|
Sort By: |
|
|
|
| |
|